| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adenovirus-Mediated Transcriptional Targeting of Colorectal Cancer and Effects on Treatment-Resistant Hypoxic Cells
|
Rajendran, Simon
|
|
2013
|
12 |
3 |
p. 152-162.e1
1469 p.
|
artikel
|
| 2 |
Adjuvant Systemic Chemotherapy After Putative Curative Resection of Colorectal Liver and Lung Metastases
|
Brandi, Giovanni
|
|
2013
|
12 |
3 |
p. 188-194
7 p.
|
artikel
|
| 3 |
Adverse Events Associated With Bevacizumab and Chemotherapy in Older Patients With Metastatic Colorectal Cancer
|
Shankaran, Veena
|
|
2013
|
12 |
3 |
p. 204-213.e1
1927 p.
|
artikel
|
| 4 |
Clinical Utility of KRAS and BRAF Mutations in a Cohort of Patients With Colorectal Neoplasms Submitted for Microsatellite Instability Testing
|
Cushman-Vokoun, Allison M.
|
|
2013
|
12 |
3 |
p. 168-178
11 p.
|
artikel
|
| 5 |
Comparison of KRAS Genotype: Therascreen Assay vs. LNA-Mediated qPCR Clamping Assay
|
Chang, Shao-Chun
|
|
2013
|
12 |
3 |
p. 195-203.e2
20106 p.
|
artikel
|
| 6 |
Discordance of KRAS Mutational Status in a Single Colonic Resection Specimen in a Patient With Colorectal Cancer: A Case Report and Review of the Literature
|
Smaglo, Brandon G.
|
|
2013
|
12 |
3 |
p. 214-217
4 p.
|
artikel
|
| 7 |
Editorial Board
|
|
|
2013
|
12 |
3 |
p. A1-
1 p.
|
artikel
|
| 8 |
FOLFIRI-Bevacizumab As First-Line Chemotherapy in 3500 Patients With Advanced Colorectal Cancer: A Pooled Analysis of 29 Published Trials
|
Petrelli, Fausto
|
|
2013
|
12 |
3 |
p. 145-151
7 p.
|
artikel
|
| 9 |
Incidence of Chemotherapy-Induced Amenorrhea in Premenopausal Women Treated With Adjuvant FOLFOX for Colorectal Cancer
|
Cercek, Andrea
|
|
2013
|
12 |
3 |
p. 163-167
5 p.
|
artikel
|
| 10 |
Table of Contents
|
|
|
2013
|
12 |
3 |
p. A2-A3
nvt p.
|
artikel
|
| 11 |
The Predictive and Prognostic Value of Sex in Early-Stage Colon Cancer: A Pooled Analysis of 33,345 Patients from the ACCENT Database
|
Cheung, Winson Y.
|
|
2013
|
12 |
3 |
p. 179-187
9 p.
|
artikel
|
| 12 |
Treatment Rationale and Study Design for a Randomized, Double-Blind, Placebo-Controlled Phase II Study Evaluating Onartuzumab (MetMAb) in Combination With Bevacizumab Plus mFOLFOX-6 in Patients With Previously Untreated Metastatic Colorectal Cancer
|
Bendell, Johanna C.
|
|
2013
|
12 |
3 |
p. 218-222
5 p.
|
artikel
|
Tijdschrift beschrijving